Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3831261 Target Snapshot

Hypoxia-inducible factor prolyl hydroxylase · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
23Compounds
10Assays
0Approved Drugs
23.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Hypoxia-inducible factor prolyl hydroxylase shows approved-linked disease relevance led by anemia (phenotype). 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q96KS0. Start with anemia (phenotype), then reuse UniProt Q96KS0 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with anemia (phenotype), then reuse UniProt Q96KS0 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
anemia (phenotype)

Hypoxia-inducible factor prolyl hydroxylase shows approved-linked disease relevance led by anemia (phenotype). 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with anemia (phenotype) because it currently carries approved-linked support. Linked drugs include DAPRODUSTAT, ROXADUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hypoxia-inducible factor prolyl hydroxylase as ChEMBL target CHEMBL3831261, mapped to UniProt Q96KS0. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hypoxia-inducible factor prolyl hydroxylase
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3831261
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96KS0
Prolyl hydroxylase EGLN2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Hypoxia-inducible factor prolyl hydroxylase is the right protein anchor across sources, using UniProt Q96KS0 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why anemia (phenotype) is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameHypoxia-inducible factor prolyl hydroxylase
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtQ96KS0
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProlyl hydroxylase EGLN2
UniProt AccessionQ96KS0
Component TypeProtein
Sequence Length407 aa

Prolyl hydroxylase EGLN2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Hypoxia-inducible factor prolyl hydroxylase, mapped to UniProt Q96KS0. ChEMBL maps the protein component as Prolyl hydroxylase EGLN2. Sequence length is 407 aa.

Mapped IDQ96KS0
Review nameHypoxia-inducible factor prolyl hydroxylase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Hypoxia-inducible factor prolyl hydroxylase shows approved-linked disease relevance led by anemia (phenotype). 5 more disease programs remain visible in the same review block.

Approved-linked Approved
anemia (phenotype)
2 linked drugs · 2 direct · 2 efficacy
Linked drugDAPRODUSTAT
Linked drugROXADUSTAT
Approved-linked Approved
anemia
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPRODUSTAT
Approved-linked Approved
chronic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugROXADUSTAT
Approved-linked Approved
chronic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPRODUSTAT
Late clinical Phase III
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugROXADUSTAT
Clinical signal Phase II
peripheral vascular disease
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPRODUSTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with anemia (phenotype) because it currently carries approved-linked support. Linked drugs include DAPRODUSTAT, ROXADUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseanemia (phenotype)
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

EC5023.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4463388 5.62 EC50 2400.0 Preclinical
CHEMBL4464252 5.58 EC50 2600.0 Preclinical
CHEMBL4459542 5.5 EC50 3200.0 Preclinical
CHEMBL4519581 5.42 EC50 3800.0 Preclinical
CHEMBL4514184 5.32 EC50 4800.0 Preclinical
CHEMBL4589866 5.3 EC50 5000.0 Preclinical
CHEMBL4472548 5.24 EC50 5800.0 Preclinical
CHEMBL4583726 5.17 EC50 6800.0 Preclinical
CHEMBL4563191 5.15 EC50 7100.0 Preclinical
CHEMBL4592450 5.12 EC50 7500.0 Preclinical
Distribution

pChEMBL Value Distribution

9
5.0
3
5.5
0
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

10
Total Assays
14
Tested Compounds
1
Assay Types
Binding — 10 assays, 14 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 10 14 5.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine